Campylobacter jejuni proteomics for new travellers' diarrhoea vaccines.
Travellers' diarrhoea is defined as diarrhoea that develops while a person is abroad in or shortly after return from a developing country. Different pathogens cause diarrhoea in travellers. Campylobacter jejuni is one of the most prominent agents for this illness. Diarrhoea is defined as an abnormally increased frequency or decreased consistency of stools for less than one week. Antibiotics are effective in preventing travellers' diarrhoea, but routine prophylaxis with antibiotics, should be discouraged. Vaccination is promising but no vaccine against C. jejuni is available at the moment. This article presents the ACE BioSciences strategy for the discovery of protein based vaccine candidates using a cell surface proteomics approach of C. jejuni. New targets for C. jejuni protein vaccines were identified. As proof of concept, we could demonstrate decreased colonization of C. jejuni in mice after vaccination with some of these candidates. It is likely that the proteomics based ACE-Biosciences approach will result in reliable travellers' diarrhoea protein-vaccines in the future.
Schrotz-King
P
P
ACE BioSciences, Drug Discovery, Unsbjergvej 2A, 5220 Odense, Denmark. schrotz@acebiosciences.com
Prokhorova
T A
TA
Nielsen
P N
PN
Crawford
J S
JS
Morsczeck
C
C
D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D002169:Campylobacter Infections / Q000517:prevention & control*; D016123:Campylobacter jejuni / Q000235:genetics*; D003967:Diarrhea / Q000517:prevention & control*; D006801:Humans; D040901:Proteomics; D014195:Travel
D001428:Bacterial Vaccines